Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
종목 코드 AVR
회사 이름Anteris Technologies Global Corp
상장일Dec 13, 2024
CEOMr. Wayne G. Paterson
직원 수136
유형Ordinary Share
회계 연도 종료Dec 13
주소860 Blue Gentian Road
도시EAGAN
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호55121
전화16514930606
웹사이트https://anteristech.com/
종목 코드 AVR
상장일Dec 13, 2024
CEOMr. Wayne G. Paterson
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음